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xxDBACKGROUND The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to
patients with advanced heart failure. The centrifugal ﬂow pump is designed for enhanced hemocompatibility by incor-
porating a magnetically levitated rotor with wide blood-ﬂow paths and an artiﬁcial pulse.
OBJECTIVES The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of
this LVAS.
METHODS Theprimary endpointwas6-month survival comparedwith INTERMACS (InteragencyRegistry forMechanically
Assisted Circulatory Support)-derived performance goal. Patients were adults with ejection fraction#25%, cardiac index
#2.2 l/min/m2 without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.
RESULTS Fifty patients were enrolled at 10 centers. The indications for LVAS support were bridge to transplantation
(54%) or destination therapy (46%). At 6 months, 88% of patients continued on support, 4% received transplants, and
8% died. Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal. Support
with the fully magnetically levitated LVAS signiﬁcantly reduced mortality risk by 66% compared with the Seattle Heart
Failure Model–predicted survival of 78% (p ¼ 0.0093). Key adverse events included reoperation for bleeding (14%),
driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modiﬁed Rankin Score >3) (8%). There
were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events. New York Heart Association
classiﬁcation, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.
CONCLUSIONS The results show that the fully magnetically levitated centrifugal-ﬂow chronic LVAS is safe, with high
30-day and 6-month survival rates, a favorable adverse event proﬁle, and improved quality of life and functional status.
(HeartMate 3 CE Mark Clinical Investigation Plan [HM3 CE Mark]; NCT02170363) (J Am Coll Cardiol 2015;66:2579–89)
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BTT = bridge to transplant
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Full MagLev = fully
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INTERMACS = Interagency
Registry for Mechanically
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INR = international normalized
ratio
LV = left ventricle/ventricular
LVAS = left ventricular assist
system
NYHA = New York Heart
Association
QOL = quality of life
SHFM = Seattle Heart Failure
Model
vWF = von Willebrand factor
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2580T reatment of advanced heart failure(HF) with a continuous-ﬂow leftventricular assist system (LVAS) is
expanding worldwide due to fewer adverse
events, improved outcomes, and broader
acceptance of the therapy (1–3). Although
the majority of patients supported by an
LVAS experience extended survival and
improved quality of life (QOL), adverse events
do occur. Older patients and those with
comorbidities carry a high risk of complica-
tions (4,5). Gastrointestinal bleeding has
emerged as an adverse event in patients with
continuous-ﬂow LVAS support (6–8), whereas
right HF, infection, stroke, and pump throm-
bosis continue to be complications associated
with signiﬁcant morbidity and mortality
(9–12). Given that patients will present for
durable LVAS support with comorbid condi-
tions, and many will require such support for
long durations, technological enhancementsthat address hemocompatibility may help reduce the
frequency and severity of these adverse events.SEE PAGE 2590Contemporary axial-ﬂow and centrifugal-ﬂow
LVASs pump blood through narrow ﬂow pathways,
which contributes to hemolysis, platelet activation,
and damage to vonWillebrand factor (vWF) (13–17). The
HeartMate 3 LVAS (St. Jude Medical, Pleasanton, Cali-
fornia) is a new, miniaturized centrifugal-ﬂow device
designed to enhance hemocompatibility byminimizing
shear force effects on blood components and by incor-
porating an optimized blood–biomaterial interface (18).
Additionally, an artiﬁcial pulse may help avoid blood
stasis within the left ventricle (LV), allowing the
aortic valve to function. These featuresmay potentially
limit the major contributing factors to hemorrhagic,
thrombotic, and infectious complications.
The purpose of this study was to evaluate the
performance and safety of this fully magnetically
levitated LVAS in patients with advanced HF. We
present the primary endpoint analysis and 6-month
results from this study conducted to meet Con-
formité Européenne (CE) mark requirements.ent of Cardiac, Thoracic, Transplantation and Vascular Surgery, H
upported by St. Jude Medical, the study sponsor. Drs. Netuka a
ants from St. Jude Medical. Dr. Sood and Ms. Damme are emplo
Zimpfer has received a research grant from St. Jude Medical; and
consultant for St. Jude Medical and HeartWare; and is on the sp
ted that they have no relationships relevant to the contents of th
received July 24, 2015; revised manuscript received SeptemberMETHODS
This single-arm, prospective, nonblinded, non-
randomized study was conducted at 10 centers in
6 countries. The study was conducted in compliance
with the Declaration of Helsinki, International Con-
ference on Harmonisation/Good Clinical Practices,
and the International Organization for Standardiza-
tion of medical devices for human subjects, known as
14155:2011, and in accordance with country-speciﬁc
requirements. Each participating center obtained
approval from their respective regulatory bodies and
ethics committees. All patients were required to
provide written informed consent. The sponsor
(St. Jude Medical) managed the study, audited the
study centers, and provided data analysis.
The primary endpoint of the study was survival
rate at 6 months compared with a performance goal
derived using INTERMACS (Interagency Registry for
Mechanically Assisted Circulatory Support) registry
data from patients matched for age, indication for
use, intra-aortic balloon pump usage, left ventricular
ejection fraction, and supported using the earlier
generation of this LVAS. Secondary study endpoints
included comparison to the predicted 6-month sur-
vival using the Seattle Heart Failure Model (SHFM)
(19); QOL (European Quality of Life Questionnaire 5
level); functional status (6-min walk test, New York
Heart Association [NYHA] functional class); adverse
event rates; and the incidence of device malfunction,
reoperation, rehospitalization, and survival free of
debilitating stroke (modiﬁed Rankin Score >3).
INTERMACS adverse event deﬁnitions were used in
this study (20). Adults with an ejection fraction #25%,
cardiac index <2.2 l/min/m2 while not on inotropes, or
inotrope-dependent status and who were either on
optimalmedicalmanagement for 45 of 60 days or listed
for transplant were enrolled in this study. The study
had a single set of entry criteria for patients designated
for bridge to transplant (BTT) or permanent support
(e.g., destination therapy [DT]). Detailed study inclu-
sion and exclusion criteria are presented in the Online
Appendix. Patients were followed to the primary
endpoint at 6 months or other outcome (transplant,
explant, or death), whichever occurred ﬁrst. Patientsannover Medical School, Hannover, Germany. This
nd Schmitto are consultants for and have received
yees of St. Jude Medical (formerly Thoratec Corpo-
is a consultant for St. Jude Medical and HeartWare.
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2581with ongoing support at 6 months will be followed for
24 months after implantation or until other outcome.
DEVICE DESCRIPTION. The new centrifugal-ﬂow
LVAS is intended to provide long-term hemodynamic
support in patients with advanced HF. This device is
designed for intrapericardial placement, with an
inﬂow conduit inserted into the LV and the outﬂow
graft attached to the ascending aorta (Figure 1). A fully
magnetically levitated (Full MagLev) rotor with large
blood-ﬂow paths (0.5 mm along the side and 1.0 mm
above and below the rotor) minimizes shear forces,
which is expected to reduce detrimental effects on
blood components (Figure 2). This rotor design avoids
the need formechanical bearings, reducing wear of the
moving component and heat generation within the
pump. The device’s internal surfaces are textured with
titaniummicrospheres to promote adhesion of patient
cells for reduced thrombogenicity. Operating in an
artiﬁcial-pulse mode, the LVAS’s rotor changes speed
every 2 s to generate pulsatile ﬂow. The pump operates
at rotor speed in the range of 3,000 to 9,000 rpm, and
the maximum ﬂow rate is 10 l/min. The pump motor
receives power from a pair of 14V lithium-ion batteries
or external AC power sources.FIGURE 1 The Fully Magnetically Levitated LVAS
Battery
Outflow
Graft Pump
Percutaneous
Cable
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The blood pump is positioned within the pericardial space,
with its integral inﬂow conduit in the left ventricle and outﬂow
graft attached to the ascending aorta. The percutaneous power
cable is tunneled through the abdominal wall and is attached to
the system controller that receives power from 2 lithium-ion
batteries. LVAS ¼ left ventricular assist system.LVAS implantation is accomplished by standard
median sternotomy and cardiopulmonary bypass
techniques. The apical cuff is sewn to the epicardial
surface near the apex of the LV, and a myocardial core
is created through the cuff with a circular knife. The
outﬂow graft is anastomosed to the ascending aorta in
the standard fashion. The pump is positioned at the
apex of the LV; the inﬂow conduit is inserted into the
LV through the apical opening and then secured by
the apical cuff. The pump power cable is tunneled
and externalized through the abdominal wall and
connected to a modular cable. The modular cable is
attached to the power and control system. Once the
outﬂow graft and pump are de-aired, cardiopulmo-
nary bypass ﬂow is decreased, and the pump is turned
on at 3,000 rpm. Following separation from cardio-
pulmonary bypass, ramped speed tests are performed
to determine a constant speed setting.
Anticoagulation guidelines include post-operative
intravenous heparin to achieve a partial thrombo-
plastin time of 45 to 65 s (1.2 to 1.8 times control) once
chest tube drainage is <50 ml/h for 3 h. The heparin is
then titrated up over 2 days until the partial throm-
boplastin time is 55 to 65 s. After the patient is able to
take oral medications, aspirin (81 to 100 mg daily) and
warfarin (or other vitamin K antagonist) are given
throughout the remainder of support with a target
international normalized ratio (INR) of 2.0 to 3.0.
STATISTICAL ANALYSIS. The primary endpoint for
patients supported by the Full MagLev LVAS was
compared with HeartMate II LVAS data using appro-
priately matched contemporary patients (n ¼ 3,103) in
the INTERMACS registry. The comparator patients
were implanted between January 1, 2012, and June 30,
2014, then followed through December 2014. All pa-
tients who did not require intra-aortic balloon use
before implantation, with an INTERMACS proﬁle be-
tween 2 and 6, age between 19 and 79 years, and a left
ventricular ejection fraction <25% were included.
Six-month survival for the comparison groupwas 88%.
The Full MagLev LVAS cohort was considered non-
inferior to the comparison group if the lower 97.5%
conﬁdence limit of the 6-month survival was within
10% of the comparison group. Continuous data are
presented as the number of subjects, mean  SD, or
median and range where appropriate. Categorical data
are reported as frequencies and percentages. Survival
data are presented using the Kaplan-Meier product
limit method as well as the percentage of subjects who
successfully reached the pre-deﬁned study endpoint.
Competing outcome analysiswas performed across the
study duration. Adverse event data are presented as
the number of patients with the event and the per-
centage of patients with events within 6 months of
FIGURE 2 Full MagLev Rotor
Flow from left ventricle
Textured surface Inflow cannula
Outflow to aorta
Rotor
Full MagLevTM
Electromagnetic motor
~0.5 mm sides
~1.0 mm top
and bottom
This cross section of this new centrifugal-ﬂow chronic blood pump shows the full magnetically levitated (Full MagLev) rotor, which allows
large pump gaps. Blood ﬂow is received from the left ventricle and is pumped through a graft attached to the ascending aorta. The top portion
of the schematic demonstrates the area of internal pump surfaces that are textured and the magnetic ﬁeld suspending the rotor. The portion
of the schematic on the right side demonstrates a magniﬁed view of the gaps around the rotor and the magnetic ﬁelds.
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2582implantation. Survival distribution between actual
survival of the novel LVAS patients and predicted
survival absent the device using SHFM was compared
using an estimated hazard ratio and Z test. Per-
centage of patients with NYHA functional class I and II
at months 1, 3, and 6 were compared to the baseline
using the Fischer exact test, whereas the 6-min walk
test and QOL data from baseline to 6 months was
compared using a paired Student t test. Statistical
analysis was completed with SAS version 9.3 (SAS
Institute, Cary, North Carolina). No adjustments for
multiplicity were made.
RESULTS
Fifty patients were enrolled into the study and
implanted with the HeartMate 3 device between June
25, 2014, and November 27, 2014, at 10 centers in
Australia, Austria, Canada, Czech Republic, Germany,
and Kazakhstan. Six-month follow-up of the last pa-
tient was reached on May 26, 2015. The patients were
representative of an advanced HF population and the
indication for support was a mix of BTT (54%) and
DT (46%) patients. Per demographics and baseline
data (Table 1), pre-implant hemodynamic values,
INTERMACS proﬁle, and medical therapy wereconsistent with chronic advanced HF. No patients
were being treatedwith amechanical circulatory assist
device at the time of implantation. The majority of
patients had 1 or more operative risk factors (Table 2).
OUTCOMES. The 30-day and 6-month survival were
98% and 92%, respectively. The lower 97.5% conﬁ-
dence limit for survival was 83%, which is within 5% of
the performance goal of 88%, thus the primary
endpoint as speciﬁed in the study was met. The SHFM
predicted a mean survival rate of 78% on continued
medical therapy at 6 months. Thus the Kaplan-Meier
actuarial survival of 92% demonstrated a 66% reduc-
tion in 6-month mortality risk with support of the
Full MagLev LVAS compared with SHFM (hazard ratio:
0.34; p ¼ 0.0093) (Figure 3).
At 6 months, 44 (88%) of the 50 patients were still
ongoing with LVAS support, 4 (8%) died, and 2 (4%)
were transplanted (Figure 4). Two patients supported
for planned BTT underwent transplantation as
intended, on post-implant days 50 and 132. The 4
deaths occurred at 2 centers within 6 months,
including 1 death within 30 days of support due to
cardiac arrest in a patient with immediate post-
operative ischemic stroke (day 19). The other deaths
were due to circulatory failure subsequent to com-
puted tomography contrast-associated anaphylactic
TABLE 1 Demographics and Baseline Clinical Parameters
Age, yrs 58.9  13.5
Male 45 (90)
BSA, m2 2.0  0.2
BMI, kg/m2 27  4.3
Ischemic etiology 22 (44)
Indication
Bridge to transplant 27 (54)
Destination therapy 23 (46)
INTERMACS proﬁle
Proﬁle 2 5 (10)
Proﬁle 3 21 (42)
Proﬁle 4 20 (40)
Proﬁle 5 3 (6)
Proﬁle 6 1 (2)
Cardiac index, l/min/m2 1.8  0.5
Left ventricular ejection fraction, % 19.0  3.7
Central venous pressure, mm Hg 9.9  5.6
Arterial blood pressure, mm Hg
Systolic 104.7  11.4
Diastolic 64.7  9.4
Mean 78.9  9.4
Pulmonary artery pressure, mm Hg
Systolic 50.8  18.6
Diastolic 23.6  9.3
Mean 33.7  12.1
Pulmonary capillary pressure, mm Hg 22.4  8.7
White blood cell count, 103/ml 7.4  2.2
Plasma-free hemoglobin, mg/dl 11.7  15.6
INR 1.3  0.6
Prothrombin time, s 24.8  28.3
Partial thromboplastin time, s 40.3  11.2
Total cholesterol, mmol/l 4.5  1.6
Lactic dehydrogenase, U/l 230  62
Medications
ACE inhibitor 21 (42)
Angiotensin II antagonist 9 (18)
Beta-blocker 36 (72)
Anticoagulant/antiplatelet drug 46 (92)
Antiarrhythmic drug 22 (44)
Inotropes 29 (58)
1 21 (42)
2 8 (16)
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; BSA ¼ body
surface area; INR ¼ international normalized ratio; INTERMACS ¼ Interagency
Registry for Mechanically Assisted Circulatory Support.
TABLE 2 Pre-Operative Risk Factors
Hypertension 33 (66)
Diabetes 12 (24)
Prior sternotomy 10 (20)
Severe COPD 3 (6)
TIA 4 (8)
Stroke 2 (4)
Renal dysfunction 21 (42)
Arrhythmia 35 (70)
Pacemaker/deﬁbrillator 40 (80)
Valve disease 41 (82)
Peripheral vascular disease 3 (6)
Left ventricular aneurysm 4 (8)
Values are n (%).
COPD ¼ chronic obstructive pulmonary disease; TIA ¼ transient ischemic attack.
FIGURE 3 Survival Analysis
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Per the Kaplan-Meier actuarial survival, support with this fully magnetically levitated
LVAS reduced 6-month mortality risk compared with Seattle Heart Failure Model (SHFM)
estimated survival with continued medical therapy. LVAS ¼ left ventricular assist system.
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2583shock and ischemic stroke determined to be unre-
lated to the implantation procedure or device (day
48), suicide (day 113), and renal failure with termi-
nation of life support (day 144). The indication for the
contrast computed tomography scan resulting in
anaphylactic shock was suspected pulmonary embo-
lism. The suicide occurred between the 3- and 6-
month follow-up and was deemed unrelated to the
device or procedure by the study site.Forty-three (86%) patients were discharged from
the hospital at amedian of 28 days (interquartile range:
22 to 43 days). Twenty-one (49%) patients were
discharged to their home, whereas 22 (51%) were dis-
charged to another intermediate medical facility
before going home. Of the 7 patients not discharged,
3 expired during index implantation hospitalization,
1 underwent heart transplantation, and 3 remained
hospitalized due to a complicated post-operative course
(pneumonia, reoperations, methicillin-resistant Sta-
phylococcus aureus infection, hemorrhagic stroke,
or ventilator dependence). Twenty-three of the 43
discharged patients (53%) were readmitted to the
hospital. The leading reasons for readmission included
FIGURE 4 Competing Outcomes Analysis
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At 6 months, 88% of patients continued on support, 4% received transplants, and
8% had died.
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2584bleeding (n ¼ 4), infection (n ¼ 6), anticoagulation
adjustment (n ¼ 5), volume issue (dehydration [n ¼ 1],
ﬂuid overload [n ¼ 1], and low ﬂow with hyponatremia
[n ¼ 1]), and chest pain (n ¼ 2). By 3 months
post-discharge, 5% of the discharged patients were
readmitted for 2 device-related or possibly device-
related events, and 28% of the discharged patients
were readmitted with 14 non–device-related events.
By 6 months post-discharge, 28% of patients were
readmitted for 15 device-related or possibly device-
related events, whereas 35% of discharged patients
were readmitted for 24 non–device-related events.
PUMP PERFORMANCE. The median duration of Full
MagLevLVAS supportwas 228days (range 19 to 335 days),
with a cumulative time of 31 years. The mean cardiac
index before implantation was 1.82  0.46 l/min/m2,
and it improved to 2.20  0.33 l/min/m2 (p < 0.0001)
after LVAS support was initiated. During the 6 months
of support, average pump ﬂow was 4.3  0.6 l/min
at 5,424  309 rpm. The artiﬁcial pulse mode
generated changes in patient arterial pulse pres-
sures (Figure 5). There were no reported events
of pump exchange, pump malfunction, or pump
thrombosis. There were no reported hemolysis
events, as evidenced by lactate dehydrogenase and
plasma-free hemoglobin levels through 6 months
(Figure 6). Laboratory values reﬂecting end-organ
function at 6-month follow-up are presented in
Table 3.ADVERSE EVENTS. Adverse events are listed by their
time to occurrence (within the ﬁrst 30 days of im-
plantation, days 31 through 180, and total time) in
Table 4; the majority occurred within 30 days of
implantation.
Bleeding was the most common adverse event
(n ¼ 19; 38%), with most occurrences during the early
post-operative period. There were 6 gastrointestinal
bleeding events in 4 patients (8%): 2 events within
30 days of implantation and 4 events after 30 days.
The INR in these patients ranged from 1.3 to 6.7.
Seven patients (14%) required surgical intervention
due to bleeding; 5 reoperations took place within
14 days of the implantation. One patient was returned
to the operating room on post-implant day 28 to
resolve bleeding in the jejunum.
Infection occurred in 18 patients (36%). Localized
infection (e.g., respiratory/pneumonia) accounted for
the majority of infections (28%), followed by sepsis
(16%) and driveline infection (10%). There were no
infections of the implanted pump.
There were 6 strokes in 6 patients (12%), of which 2
(4%) occurred in the perioperative period. Four of the
6 strokes (8%) were considered debilitating (modiﬁed
Rankin Scale >3). Of these, 1 ischemic stroke occurred
the day after index LVAS implantation where there
was difﬁculty in properly engaging the inﬂow conduit
with the apical cuff. This patient expired on day 19.
The second that was ischemic in nature was subse-
quent to anaphylactic shock after the patient received
contrast medium for a lung scan. This patient expired
on day 48. The third, a hemorrhagic stroke, occurred a
day after transcatheter aortic valve replacement. This
patient had pre-existing aortic valve disease with
bioprosthetic valve replacement during the primary
implantation. By month 1, structural deterioration of
the valve was observed with moderate aortic regurgi-
tation requiring transcatheter aortic valve replace-
ment. The latter 2 strokes appear to have a temporal
relationship with other procedures performed while
on LVAS support. The fourth stroke was hemorrhagic
in nature and occurred on day 103. This patient further
had renal failure with stoppage of life support.
Right HF occurred in 5 patients; 4 instances occurred
during the ﬁrst 30 days of support. Of these, 2 (4%)
patients required right ventricular device implantation
during initial implant surgery; of these 2, 1 patient
required extracorporeal membrane oxygenation, which
was subsequently discontinued (post-implant day 103),
and 1 required short-term right ventricular assist device
support (CentriMag, St. Jude Medical), which was
removed at the time of heart transplantation (post-
implant day 50). The remaining patients with right
HF were supported with inotropes for >7 days.
FIGURE 5 Hemodynamic Monitor Snapshot
In this patient with the fully magnetically levitated LVAS, the arterial pulsatility generated by the device can be seen in the red line (labeled Art). Photo
courtesy of the Institute for Clinical and Experimental Medicine, Prague, Czech Republic. LVAS ¼ left ventricular assist system.
FIGURE 6 LDH and PlHgb Laboratory Values Over Time
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There were no hemolysis events per mean ( SD) for lactic dehydrogenase (LDH) and plasma hemoglobin (PlHgb) at baseline to month 6.
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TABLE 3 Laboratory Values
Baseline Week 1 Month 1 Month 3 Month 6
AST, U/l 28.9  12.2 48.3  56.7* 28.6  14.7 29.9  26.5 25.8  7.8
ALT, U/l 33.3  20.8 37.0  50.2 26.9  22.2 24.9  25.0 21.5  8.7*
Total bilirubin,
mmol/l
18.8  10.1 24.0  30 11.5  5.5* 9.5  4.6* 10.7  4.8*
Creatinine, mmol/l 112.0  31.6 97.1  29* 101.2  56.7 96.2  28.7* 99.8  23.7*
Hemoglobin, g/dl 13.2  2.0 9.4  1.8* 10.3  1.6* 11.8  2.0* 12.8  2.0
Hematocrit, % 39.5  5.6 28.8  3.9* 31.5  5.0* 36.0  6.3* 38.4  5.8
Platelets, 103/ml 231  69.3 212  82.4 322  129* 256  83.3 237  64.7
Sodium, mmol/l 136.0  3.6 137.5  6.6 135.0  5.6 137.5  4.4 138.0  4.2*
BUN, mmol/l 9.1  5.3 9.4  7.8 8.8  9.5 8.6  7.6 7.4  4.4*
Values are mean  SD. *p < 0.05 when compared with baseline using the paired Student t test.
AST ¼ aspartate aminotransferase; ALT ¼ alanine aminotransferase; BUN ¼ blood urea nitrogen.
TABLE 4 Adverse Ev
Adverse Event
Bleeding
Requiring surgery
GI bleeding
Cardiac arrhythmias
Infection
Sepsis
Driveline
Stroke*
Ischemic
Hemorrhagic
Neurological dysfunctio
other†
Device thrombosis
Device malfunction
Hemolysis
Psychiatric episode
Renal dysfunction
Hepatic dysfunction
Respiratory failure
Right heart failure
Requiring RVAD
Wound dehiscence
Other event‡
Values are n (%). *Include
1 following anaphylactic s
procedure. †Seizure (n ¼ 2)
(n ¼ 1), volume status (n ¼
GI ¼ gastrointestinal; RV
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2586FUNCTIONAL STATUS AND QOL. All patients were
NYHA functional class IIIB or IV before implantation,
which improved signiﬁcantly (p < 0.0001) at 1, 3,
and 6 months (Figure 7). Improvement in 6-min
walk distance was demonstrated by comparison of
individual patient paired data at baseline to 1, 3, and
6 months, respectively, which were signiﬁcant
(p < 0.0001) at the 3- and 6-month intervals
(Figure 8). QOL assessment by the Visual Analogents Through 6 Months
Days 0–30
(n ¼ 50)
Days >30
(n ¼ 49)
All (6 Months)
(n ¼ 50)
Patients Events Patients Events Patients Events
15 (30) 19 8 (16) 16 19 (38) 35
6 (12) 6 2 (4) 2 7 (14) 8
2 (4) 2 3 (6) 4 4 (8) 6
14 (28) 14 3 (6) 3 17 (34) 17
10 (20) 14 12 (24) 14 18 (36) 28
4 (8) 4 4 (8) 4 8 (16) 8
1 (2) 1 4 (8) 4 5 (10) 5
2 (4) 2 4 (8) 4 6 (12) 6
2 (4) 2 2 (4) 2 4 (8) 4
0 (0) 0 2 (4) 2 2 (4) 2
n 2 (4) 2 2 (4) 2 4 (8) 4
0 (0) 0 0 (0) 0 0 (0) 0
0 (0) 0 0 (0) 0 0 (0) 0
0 (0) 0 0 (0) 0 0 (0) 0
1 (2) 1 2 (4) 2 3 (6) 3
5 (10) 5 0 (0) 0 5 (10) 5
1 (2) 1 0 (0) 0 1 (2) 1
7 (14) 7 1 (2) 1 8 (16) 8
4 (8) 4 1 (2) 1 5 (10) 5
2 (4) 2 0 (0) 0 2 (4) 2
2 (4) 2 2 (4) 2 4 (8) 4
18 (36) 35 19 (39) 25 27 (54) 60
s 3 procedural-related events: 1 implant issue (difﬁculty engaging inﬂow conduit),
hock from contrast media, and 1 following transcatheter aortic valve implantation
and transient ischemic attack (n ¼ 2). ‡Other adverse events include pleural effusion
5), high/low INR (n ¼ 7), and various (n ¼ 10).
AD ¼ right ventricular assist device.Score paired by individual patients improved from 50
at baseline to 70 at 3 months and 75 at 6 months
(p < 0.0001).
DISCUSSION
This ﬁrst clinical study with this new centrifugal-ﬂow
chronic LVAS has successfully demonstrated the
safety and performance of this device in an advanced
HF population (Central Illustration), including patients
requiring BTT or DT under a single set of entry criteria.
Survival rates of 98% at 30 days and 92% at 6 months
compare well with the reported survival in prior
studies involving BTT or DT indications (1,3,21–31).
Additionally, compared with an SHFM-predicted
6-month survival of 78%, support with this new de-
vice was associated with a mortality risk reduction of
66%. Patients had marked impairment of functional
status and QOL at baseline; both showed signiﬁcant,
progressive, and sustained improvement over time.
The device performed as intended, without pump
malfunctions requiring pump exchanges, pump
thrombosis, or hemolysis. The adverse event types and
rates are consistentwith expected complications in the
advanced HF population.
The most frequent adverse event following LVAS
implantation, bleeding, varies by patient-deﬁned
variables such as age, sex, body mass index, and eti-
ology of HF (32). The risk of bleeding during LVAS
support is also dependent on device- and procedure-
related variables, including the extent of surgery for
implantation, reactions at the blood–biomaterial
interface, and the amount of damage to blood com-
ponents by shear stress. Reported bleeding rates vary
greatly due to differences in deﬁnitions and methods,
but approximately 60% of all patients implanted with
an LVAS experience surgical, gastrointestinal, or
other bleeding events during support, with incidence
of bleeding peaking within the ﬁrst 3 months post-
implant (33). Early post-operative bleeding requiring
reoperation and transfusion has been reported as one
of the most common adverse events in previous LVAS
studies (22,28,30). Overall bleeding frequency and
need for reoperation due to bleeding in this study is
considerably less than reported in prior BTT and DT
studies (22,23,30,34).
Placement of the Full MagLev LVAS in the thorax
eliminates the need to surgically create an abdominal
pocket, thereby reducing the amount of surgery
required. The wide blood-ﬂow gaps within the rotor,
which are 20 times greater than similar devices, might
contribute to lower shear stress to minimize hemoly-
sis, platelet activation, and damage to the vWF.
Although vWF preservationwas not directly evaluated
FIGURE 7 Functional Capacity
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Compared with baseline, patients had improved walk distances at 1, 3, and 6 months.
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2587in this study, the rate of gastrointestinal bleeding we
observed (8%) was lower than the 11% to 25% reported
for other devices (28,34,35). Reoperations with multi-
ple blood transfusions and prolonged time in intensive
care are major contributing factors to the development
of infections, a leading cause of morbidity and mor-
tality of LVAS-supported patients. Total infection rates
have been as high as 50%, with device-related infec-
tion (mostly of the driveline exit site) seen in approx-
imately 20% of patients (1,22,30). The overall infection
rate in this study was 36%, with only 10% of patients
having a driveline infection. Drivelines were exter-
nalized through circular incisions with the same
diameter as the driveline, and the silicone portion of
the driveline was positioned to be the interface with
the subcutaneous tissue, a practice known to help
reduce site infection (36). Elimination of the abdom-
inal pump pocket and low bleeding rates, particularly
events requiring surgery and transfusion, as well as
improved techniques for driveline externalization
may have contributed to the low observed rate of
infection.
Complete LV unloading during continuous-ﬂow
LVAS support often results in constant closure of
the aortic valve, with eventual valve commissure
fusion and/or aortic insufﬁciency (37,38). Varying the
LV volume and pressure with the artiﬁcial pulse mode
should facilitate intermittent aortic valve movement
to avoid fusion and insufﬁciency. The effects of
the artiﬁcial pulse mode could not be assessed due to
the short follow-up time.
Stroke occurs in approximately 7% to 15% of
patients undergoing long-term LVAS support (3,28).
With an overall lower adverse event rate, particu-
larly bleeding and infection, and the absence of
hemolysis and pump thrombosis, the 12% stroke
rate (8% debilitating stroke) observed in this study
was higher than expected. However, one-half
(n ¼ 3) of the events appear to be related to an
implant procedure issue or other procedures and
may not represent recurring risk. A longer follow-up
duration and larger future clinical studies with this
Full MagLev LVAS will provide an opportunity to
better evaluate the frequency of adverse events
observed in this study.
Adverse events associated with LVAS support,
along with limitations in daily activities due to
external drivelines and power supplies, require
these patients to make personal adjustments due to
their use of this technology. However, with this
new LVAS, signiﬁcant improvement was observed in
both functional capacity and QOL in patients with
advanced HF, similar to that achieved by other
LVASs (28,34).STUDY LIMITATIONS. The main limitation of this
study was its lack of randomization and controls. Due
to the inclusion of all patients meeting the criteria for
advanced HF and without delineation by indication
(BTT or DT), direct comparison to other contemporary
LVAS studies cannot be done. However, the use of
INTERMACS data from the earlier-generation device
patients to establish the performance goal was appli-
cable because these patients were supported for both
BTT and DT. Although all centers participating in this
CENTRAL ILLUSTRATION Support With Magnetically Levitated LVAS: HeartMate 3 CE Mark Trial Results Summary
Netuka, I. et al. J Am Coll Cardiol. 2015; 66(23):2579–89.
In 50 patients placed on the fully magnetically levitated pump left ventricular assist system (LVAS), use of the system reduced mortality risk and
improved functional capacity and quality of life. Although there were no instances of pump failure, thrombosis, or hemolysis, key adverse events including
bleeding, infection, and stroke did occur; 14% of patients required reoperation for bleeding. BTT ¼ bridge to transplant; DT ¼ destination therapy;
PG ¼ performance goal; SHFM ¼ Seattle Heart Failure Model.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Me-
chanical LVAS are associated with substantial survival
beneﬁt compared with medical therapy in patients
with end-stage HF, but complications related to
hemocompatibility currently limit broader utilization.
TRANSLATIONAL OUTLOOK: Additional research
is needed to determine whether LVAS with magneti-
cally levitated rotors will reduce the risks of throm-
boembolism, bleeding, and structural deterioration of
the aortic valve.
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2588study are experienced with LVAS technology and HF
care, differences in surgical technique and medical
management may exist. The follow-up time presented
in this report was short; however, patients will be
followed until outcome or 24 months, and a separate
randomized clinical trial is ongoing in the United
States.
CONCLUSIONS
The ﬁrst human experience with the new HeartMate 3
LVAS has demonstrated that the pump performs as
designed and is safe in an advancedHF population that
included a mix of both BTT and permanent-support
patients under a single set of study entry criteria.
Adequate circulatory support without pump mal-
functions requiring pump exchanges, and the absence
of pump thrombosis or hemolysis demonstrated de-
vice performance. Survival rates at 30 days and
6 months were high, with a favorable adverse event
proﬁle. Patient functional status and QOL showed
progressive and sustained improvement over time.
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APPENDIX For an expanded Methods sec-
tion, please see the online version of this
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